ALLRAllarity TherapeuticsSigning up patients
Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer
Advanced Ovarian Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 40 (planned)
- Started
- Apr 15, 2019
- Main results expected
- Mar 2027
- Fully finished
- Sep 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Evaluate the optimal dose of 2X-121 as single agent therapy
Measured over: From enrollment up to approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT03878849 · record last updated 2025-08-28 · checked 2026-11-09 15:47 UTC